Drugs.com - FDA MedWatch Alerts

Drug Safety Communication: Ocaliva (obeticholic acid) - Serious Liver Injury Being Observed in Patients without Cirrhosis

Audience: Gastroenterology, Hepatology, Patient, Health Care Professional, Pharmacy ISSUE: The FDA identified cases of serious liver injury among patients being treated for primary biliary cholangitis (PBC) with Ocaliva (obeticholic acid) who did...

Feb 9, 2025 - 21:44
 0
Drug Safety Communication: Ocaliva (obeticholic acid) - Serious Liver Injury Being Observed in Patients without Cirrhosis
Audience: Gastroenterology, Hepatology, Patient, Health Care Professional, Pharmacy ISSUE: The FDA identified cases of serious liver injury among patients being treated for primary biliary cholangitis (PBC) with Ocaliva (obeticholic acid) who did...
Read More

Tags:

Previous Article

FDA Adds Boxed Warning to Veozah (fezolinetant) to Highlight the Known Risk of R...

Next Article

Buy-herbal.com Issues Voluntary Nationwide Recall of Nhan Sam Tuyet Lien Truy Ph...

Related Posts

Endo USA, Inc. Issues Recall of One Lot of Clonazepam Orally Disintegrating Tablets Due to Mislabeling: Incorrect Strength on Product Carton

Endo USA, Inc. Issues Recall of One Lot of Clonazepam O...

Feb 9, 2025  0

ICU Medical Issues Nationwide Recall of Potassium Chloride Injection, 20 mEq and Potassium Chloride Injection, 10 mEq Due to Mislabeling

ICU Medical Issues Nationwide Recall of Potassium Chlor...

Feb 16, 2025  0

Drug Safety Communication: FDA Adds Warning About Rare Occurrence of Serious Liver Injury with Use of Veozah (fezolinetant) for Hot Flashes Due to Menopause

Drug Safety Communication: FDA Adds Warning About Rare ...

Feb 9, 2025  0